A new phase 3 trial indicates that semaglutide, a drug developed by Novo Nordisk, may enable some children with severe obesity to lose enough weight to fall below clinical thresholds, raising both hope and questions about early intervention.
A new late-stage trial from Danish drugmaker Novo Nordisk has added to the evidence that semaglutide may help some younger children with obesity lose enough weight to move out of the condition’s clinical range. In the STEP Young study, 40.4% of children aged six to under 12 who received the once-weekly treatment were no longer classified as having obesity after 68 weeks, while none in the placebo group reached that milestone, according to reporting on the results by Nordic Life Science and other industry outlets.
The trial enrolled 165 children, most of whom were living with severe obesity at the start of the study. It also paired the medicine with lifestyle measures, including a reduced-calorie diet and increased physical activity in both groups. That means the difference between the two arms reflects the added effect of semaglutide on top of behavioural changes, rather than medication alone. Novo Nordisk said the study met its main goal by showing a greater reduction in body mass index, or BMI, among children given semaglutide.
For doctors and parents, the findings are significant because childhood obesity can set the stage for later type 2 diabetes, fatty liver disease, high blood pressure and other long-term health problems. But the results also raise difficult questions about how early drug treatment should begin, how long it should continue and whether families can realistically access it. The safety data from this study are reassuring only in the short term, and they do not answer concerns about years of exposure during growth and development.
That is why specialists stress that medication cannot be a stand-alone answer. Diet, exercise, sleep, limits on screen time and family-wide changes in eating habits remain central, especially in places such as India, where obesity can coexist with nutritional deficiencies. Novo Nordisk’s results may point to a useful tool for selected children with severe obesity, but the broader message is that treatment must still be individualised, closely monitored and built around healthy habits.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
